Alivus Life Sciences Limited announces acquisition via board meeting outcome

M&A / JV 18 Aug 2026 · Announced· ✓ Verified

Alivus Life Sciences Limited, a listed pharmaceutical company, notified both NSE and BSE of a board resolution approving an acquisition under SEBI (LODR) Regulation 30. The outcome filing provides no detail on target identity, purchase price, asset class, or closing conditions-standard for early-stage M&A announcements under Indian disclosure norms, which permit staged disclosure once material terms crystallise. The transaction likely triggered mandatory review under the SEBI takeover code (if the target is listed) or CCI merger thresholds (if combined turnover or assets exceed ₹1,000 crore), pending release of full particulars.

Why it mattersThe Regulation 30 disclosure regime requires listed entities to announce material acquisitions immediately post-board approval, triggering standstill and pricing transparency duties; the bare intimation signals either a confidentiality period (vendor lock-in) or Phase 1 of a two-stage disclosure process.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals